IceCure MedicalICCM
ICCM
About: Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Employees: 64
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
39% more capital invested
Capital invested by funds: $121K [Q3] → $169K (+$47.2K) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.13% less ownership
Funds ownership: 0.41% [Q3] → 0.28% (-0.13%) [Q4]
13% less funds holding
Funds holding: 15 [Q3] → 13 (-2) [Q4]
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for ICCM.
Financial journalist opinion
Neutral
PRNewsWire
2 days ago
Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery
Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® users including Dr. Kizuki Matsumoto and Dr. Eisuke Fukuma Patients who underwent cryoablation compared to breast-conserving therapy (BCT) reported significantly higher satisfaction (71.0±18.6 vs. 56.3±16.5) in the primary outcome with a mean follow-up of 4.2 and 4.0 years, respectively Data support continued move toward de-escalation of breast cancer treatment from BCT (lumpectomy) to nonsurgical options including cryoablation CAESAREA, Israel , March 10, 2025 /PRNewswire/ -- IceCure Medical Ltd.
Neutral
PRNewsWire
2 weeks ago
IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel
Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing demand CAESAREA, Israel , Feb. 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has filed for regulatory approval with the Medical Device Division ("AMAR") of Israel's Ministry of Health for its next-generation single cryoprobe cryoablation system, the XSense™ System and CryoProbes.
Neutral
PRNewsWire
1 month ago
IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision
Two independent studies of ProSense® cryoablation in breast cancer were presented, one of which won the Highest Scoring Abstract Award in its category Hands-on ProSense® training featured during the SIO Mini Masterclass on Breast Cryoablation; the session was extremely well attended with presentations led by interventional oncology and breast cancer thought leaders FDA's decision on ProSense® market authorization for early-stage breast cancer expected Q1 2025 CAESAREA, Israel , Feb. 4, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation as one of the sponsors of the Breast Cryoablation Mini Masterclass held during the 2025 Society of Interventional Oncology (SIO) Annual Meeting in Las Vegas, which took place January 29 to February 3, 2025.
Neutral
PRNewsWire
1 month ago
IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China
Seeks to expand regulatory approval in China where IceSense3 has already been approved CAESAREA, Israel , Jan. 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has submitted a regulatory filing with China's National Medical Products Administration ("NMPA") for the approval of its ProSense® Cryoablation System.
Neutral
PRNewsWire
1 month ago
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America
Increase in sales of ProSense®, based on preliminary unaudited results, demonstrate growing adoption of ProSense® cryoablation for breast tumors. FDA decision on market authorization of ProSense® for early-stage breast cancer is expected in the first quarter of 2025.
Neutral
PRNewsWire
2 months ago
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule
CAESAREA, Israel , Jan. 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a notification letter from Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Rule").
Neutral
PRNewsWire
2 months ago
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology
XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel , Jan. 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received an Intention to Grant Notice from the European Patent Office for its invention titled "Cryogenic System Connector".
Neutral
PRNewsWire
2 months ago
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting
ICE3 trial results presented by ICE3 Co-Principal Investigator Dr. Kenneth Tomkovich FDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025 FDA's marketing authorization decision expected in Q1, 2025 CAESAREA, Israel , Dec. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that data from its ICE3 trial of ProSense's® in early-stage breast cancer were presented at the Radiological Society of North America's 2024 Annual Meeting on December 5, 2024 in Chicago, IL.
Neutral
Seeking Alpha
3 months ago
IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM ) Q3 2024 Earnings Conference Call November 26, 2024 10:00 AM ET Company Participants Michael Polyviou - IR Ronen Tsimerman - CFO and Chief Operating Officer Tlalit Tel-Tzure - VP of Business Development and Global Marketing Shay Levav - VP of Regulatory and Quality Affairs and Clinical Applications Conference Call Participants Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Yi Chen - H.C. Wainwright Operator Good morning, and thank you for standing by.
Negative
Zacks Investment Research
3 months ago
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07.
Charts implemented using Lightweight Charts™